Cargando…
Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines
Bupropion is widely used for treating bipolar disorder (BD), and especially those with depressive mood, based on its good treatment effect, safety profile, and lower risk of phase shifting. However, increasing evidence indicates that the safety of bupropion in BD patients may not be as good as previ...
Autores principales: | Li, Dian-Jeng, Tseng, Ping-Tao, Chen, Yen-Wen, Wu, Ching-Kuan, Lin, Pao-Yen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998539/ https://www.ncbi.nlm.nih.gov/pubmed/27043678 http://dx.doi.org/10.1097/MD.0000000000003165 |
Ejemplares similares
-
Significantly Higher Prevalence Rate of Asthma and Bipolar Disorder Co-Morbidity: A Meta-Analysis and Review Under PRISMA Guidelines
por: Wu, Ming-Kung, et al.
Publicado: (2016) -
Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls: A Meta-Analysis and Review Under Guideline of PRISMA
por: Tu, Kun-Yu, et al.
Publicado: (2016) -
Bone Mineral Density in Schizophrenia: An Update of Current Meta-Analysis and Literature Review Under Guideline of PRISMA
por: Tseng, Ping-Tao, et al.
Publicado: (2015) -
Significantly higher peripheral fibroblast growth factor-2 levels in patients with major depressive disorder: A preliminary meta-analysis under MOOSE guidelines
por: Wu, Ching-Kuan, et al.
Publicado: (2016) -
A meta-analysis and systematic review of the comorbidity between irritable bowel syndrome and bipolar disorder
por: Tseng, Ping-Tao, et al.
Publicado: (2016)